ArticleOxford medical case reports2026
Severe Euglycemic diabetic ketoacidosis with mixed Acid-Base disorder following acetazolamide initiation in type 2 diabetes: a case report and review of literature.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Euglycemic diabetic ketoacidosis (euDKA) is an increasingly recognized complication of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy, characterized by severe metabolic acidosis with near-normal blood glucose levels. We report a rare case of a 45-year-old woman with type 2 diabetes mellitus who presented with severe euDKA (pH 6.85, glucose 170 mg/dl) following initiation of acetazolamide for glaucoma management. Clinical evaluation revealed profound metabolic acidosis with bicarbonate 1.5 mmol/l and anion gap 27 mmol/l. Delta ratio calculation (0.64) revealed a mixed high anion gap and normal anion gap metabolic acidosis, indicating dual pathophysiology: ketoacid accumulation from euDKA and acetazolamide-induced renal bicarbonate wasting. Immediate acetazolamide discontinuation combined with aggressive fluid resuscitation, insulin infusion, and sodium bicarbonate resulted in complete metabolic correction by Day 3 without hemodialysis. To our knowledge, this rare combination of SGLT2 inhibitor use and acetazolamide underscores the need for careful medication reconciliation and multidisciplinary communication in diabetic patients to prevent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.